To Evaluate the Efficacy of Three Times Weekly (TIW) Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 353 participants.

Also called NCT06901505

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 353 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT06901505
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT06901505. Randomized; no masking; primary purpose treatment. Start 2025-07-24 (actual); primary completion 2026-08-12 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
To Evaluate the Efficacy of Three Times Weekly (TIW) Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis
Condition
Anemia of Chronic Kidney Disease
Intervention (Drug)
Erythropoiesis-Stimulating Agent (ESA)
Intervention (Drug)
Vadadustat
Lead sponsor
Akebia Therapeutics (class: industry)

Record details

Record id
cardio:ct-nct06901505
Content hash
1833a7181c4e14c5269d6ef0696772437cbcc6b772faadba805e237cf2f617e4